Àvida Biotech is developing broad-spectrum antiviral products to prevent neglected and emerging infectious diseases. These products will be oral and thermostable, which reduces their overall cost and will make them widely affordable to achieve maximal impact. Our main focus is on dengue, chikungunya and zika. We have proof of concept of oral vaccination in a mouse model of dengue.
In GlyProVac we identify and develop novel subunit vaccine candidates harbouring natural and highly immunogenic O-linked protein glycosylations. Our proprietary technology BEMAP allows an unbiased proteome wide screening for protein glycosylation which continues to reveal a staggering number of glycoproteins in vaccine relevant bacterial pathogens with an unmet medical need. These modifications drastically influence the topology of the protein and are particularly well recognized by the human immune response. We are currently working to establishing this novel bacterial vaccine concept in the E. coli family (for diarrhoea and urinary tract infection).
Aivita Bimedical Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to develop cutting-edge therapies and commercial products that improve quality of life. AIVITA has developed a next-generation, personalized cancer immunotherapy that primes the patient’s immune system to target tumor-initiating cells, the very cells which drive the growth and spread of the disease. Successive improvements in manufacturing at AIVITA have made this personalized treatment reliable, quick, and economical to produce. The Company is currently conducting three clinical studies investigating its platform immunotherapy in patients with ovarian cancer, glioblastoma and melanoma. AIVITA uses 100% of proceeds from the sale of its ROOT of SKIN™ skincare line to support the treatment of women with ovarian cancer.
One Health Ventures’ (OHV)
is an early stage company, which has developed a proprietary, recombinant, genetic toxoid vaccine candidate against epsilon toxin (ETX), which can be cultured in E.coli, as a treatment for both animals and humans. The vaccine has been successfully trialed in mice, rabbits and sheep and the next step is to seek approval for and then to carry out a Phase 1 trial. ETX is produced from a common bacteria Clostridium perfringens Types B/D and causes a fatal disease, enterotoxaemia, principally in sheep and goats.
Over the past 7 years, ETX has also been implicated as the trigger for Multiple Sclerosis (MS), which affects about 2.5 million people worldwide and for which there is currently no cure or human vaccine. Significant levels of ETX, antibodies to ETX and the relevant bacterial strains have all been found in MS patients and to a lesser extent in controls. OHV is seeking a commercial partner(s) either to licence or enter into a joint venture(s) in order to take this project forward.
Vaximiser is a private companay operating globally with partnerships with vaccine companies and their suppliers. Their core IP is new market-ready eggs and cells to maximise vaccine production. Vaximiser is also developing revolutionary adjuvant systems. Vaximiser is currently scaling their products, working with existing supply chains, and conducting commercial scale trials. https://vaximiser.com/